DK2865421T3 - Bittersmagsreceptoragonister til topisk anvendelse - Google Patents

Bittersmagsreceptoragonister til topisk anvendelse Download PDF

Info

Publication number
DK2865421T3
DK2865421T3 DK13190536.6T DK13190536T DK2865421T3 DK 2865421 T3 DK2865421 T3 DK 2865421T3 DK 13190536 T DK13190536 T DK 13190536T DK 2865421 T3 DK2865421 T3 DK 2865421T3
Authority
DK
Denmark
Prior art keywords
cells
human
bitter taste
receptor
bitter
Prior art date
Application number
DK13190536.6T
Other languages
English (en)
Inventor
Christoph Schempp
Ute Woelfle
Original Assignee
Univ Freiburg Albert Ludwigs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Freiburg Albert Ludwigs filed Critical Univ Freiburg Albert Ludwigs
Application granted granted Critical
Publication of DK2865421T3 publication Critical patent/DK2865421T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/76—Salicaceae (Willow family), e.g. poplar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (4)

1. Ligand til en bittersmagsreceptor (T2R) til anvendelse til behandling af en hudforstyrrelse, hvor liganden administreres topisk på huden, og hvor liganden er amarogentin.
2. Ligand til anvendelse ifølge krav 1, hvor bittersmagsreceptoren er smagsreceptor 2 type 1 (T2R1).
3. Ligand til anvendelse ifølge krav 1, hvor hudforstyrrelsen er valgt fra gruppen, der består af pruritus, urticaria, dermatitis, eksem og kombinationer deraf.
4. Farmaceutisk sammensætning til topisk anvendelse til behandling af en hudforstyrrelse, som omfatter en ligand til en bittersmagsreceptor som defineret i krav 1, hvor sammensætningen er en salve, en lotion, en creme eller en gel.
DK13190536.6T 2013-10-28 2013-10-28 Bittersmagsreceptoragonister til topisk anvendelse DK2865421T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13190536.6A EP2865421B1 (en) 2013-10-28 2013-10-28 Bitter taste receptor agonists for topical use

Publications (1)

Publication Number Publication Date
DK2865421T3 true DK2865421T3 (da) 2018-09-10

Family

ID=49518688

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13190536.6T DK2865421T3 (da) 2013-10-28 2013-10-28 Bittersmagsreceptoragonister til topisk anvendelse

Country Status (5)

Country Link
EP (1) EP2865421B1 (da)
DK (1) DK2865421T3 (da)
ES (1) ES2684722T3 (da)
PL (1) PL2865421T3 (da)
RU (1) RU2014143205A (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102512776B1 (ko) * 2015-12-24 2023-03-21 주식회사 엘지생활건강 아브신틴을 포함하는 피부상태 개선용 조성물
CN109045022A (zh) * 2018-07-03 2018-12-21 厦门大学 阿加来必在制备Stargardt黄斑变性疾病的药物中的用途
CN111297861B (zh) * 2020-03-12 2023-03-10 深圳大学 奎宁及其药学上可接受的盐在制备治疗特应性皮炎的药物中的用途
CN113425722A (zh) * 2020-03-23 2021-09-24 上海市浦东新区公利医院(第二军医大学附属公利医院) 苦味受体激动剂及其在预防和治疗SARS-CoV-2相关传染病中的应用
FR3115694B3 (fr) * 2020-10-30 2022-10-28 Soc De Courtage Et De Diffusion Codif International Principe actif constitué d’un extrait de pomme amère activant des récepteurs à l’amertume Tas2Rs présents sur la peau humaine et utilisations cosmétiques et dermato-cosmétiques correspondantes.
CN113278026B (zh) * 2021-05-29 2022-05-13 南京中医药大学 一种具有抗肿瘤活性的苦木素类化合物及其制备方法和应用
CN115137735A (zh) * 2022-06-30 2022-10-04 华中科技大学协和深圳医院 苦龙胆酯苷及其药学上可接受的盐在制备治疗皮炎的药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004210656A (ja) * 2002-12-27 2004-07-29 Daicho Kikaku:Kk 皮膚用剤
KR101509449B1 (ko) * 2008-06-05 2015-04-08 (주)아모레퍼시픽 카페인을 함유하는 슬리밍용 첩부제
JP2010229124A (ja) * 2009-01-30 2010-10-14 Kowa Co ジフェンヒドラミン含有溶液充填カプセル剤
US9579315B2 (en) * 2010-08-09 2017-02-28 University Of Maryland, Baltimore Methods of treating obstructive lung diseases using bitter tastants
WO2013112865A1 (en) * 2012-01-27 2013-08-01 The Trustees Of The University Of Pennsylvania Diagnosis and treatment for respiratory tract diseases
US20140107025A1 (en) * 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
EP2735302A1 (en) * 2012-11-22 2014-05-28 KAIROSmetics UG Topical composition comprising a hop extract and containing 8-prenyl naringenin, and uses thereof

Also Published As

Publication number Publication date
EP2865421A1 (en) 2015-04-29
PL2865421T3 (pl) 2018-10-31
EP2865421B1 (en) 2018-05-30
RU2014143205A (ru) 2016-05-20
ES2684722T3 (es) 2018-10-04

Similar Documents

Publication Publication Date Title
DK2865421T3 (da) Bittersmagsreceptoragonister til topisk anvendelse
Yang et al. Nrf2 promotes keratinocyte proliferation in psoriasis through up-regulation of keratin 6, keratin 16, and keratin 17
Ryskamp et al. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease
Jhamandas et al. Actions of β-amyloid protein on human neurons are expressed through the amylin receptor
Roberts-Thomson et al. ORAI-mediated calcium entry: mechanism and roles, diseases and pharmacology
US7575882B2 (en) Compositions and methods for identifying modulators of TRPV2
Procino et al. Combination of secretin and fluvastatin ameliorates the polyuria associated with X-linked nephrogenic diabetes insipidus in mice
Nguyen et al. Synergistic control of keratinocyte adhesion through muscarinic and nicotinic acetylcholine receptor subtypes
Maradana et al. Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis
Li et al. The NALP1 inflammasome controls cytokine production and nociception in a rat fracture model of complex regional pain syndrome
EP3149478B1 (en) Senescent cell biomarkers
Bin et al. An acrodermatitis enteropathica-associated Zn transporter, ZIP4, regulates human epidermal homeostasis
Bobulescu et al. Acute regulation of renal Na+/H+ exchanger NHE3 by dopamine: role of protein phosphatase 2A
Halbach et al. Oxytocin expression and function in the posterior retina: a novel signaling pathway
Coppa et al. The peroxisomal fatty acid transporter ABCD1/PMP-4 is required in the C. elegans hypodermis for axonal maintenance: A worm model for adrenoleukodystrophy
Yang et al. Sequential changes of endoplasmic reticulum stress and apoptosis in myocardial fibrosis of diabetes mellitus-induced rats
Sun et al. Methamphetamine produces cardiac damage and apoptosis by decreasing melusin
Lee et al. Maintenance of stem cell niche integrity by a novel activator of integrin signaling
Ögren et al. Galanin and learning
Molteni et al. STIM proteins and Orai Ca2+ channels are involved in the intracellular pathways activated by TLQP-21 in RAW264. 7 macrophages
US20230159601A1 (en) Pharmaceutical composition for lowering blood cholesterol, preventing or treating cardiovascular diseases and reducing inflammation
Dai et al. Myeloid Vamp3 deletion attenuates CFA-induced inflammation and pain in mice via ameliorating macrophage infiltration and inflammatory cytokine production
Boulan et al. CRMP4-mediated fornix development involves Semaphorin-3E signaling pathway
Danish et al. Functional pleiotropy of calcium binding protein regucalcin in signaling and diseases
Nedi et al. Tissue dependent differences in G-protein coupled receptor kinases associated with 5-HT4 receptor desensitization in the rat gastro-intestinal tract